| Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| EcoR1 Capital, LLC | 10% Owner | May 05 | Buy | 29.02 | 1,062,736 | 30,840,599 | 11,584,280 | May 09 06:01 AM | | EcoR1 Capital, LLC | 10% Owner | May 05 | Sale | 29.02 | 1,062,736 | 30,840,599 | 11,584,280 | May 09 06:01 AM | | Cooke Shane | Director | Apr 11 | Option Exercise | 6.41 | 5,000 | 32,050 | 5,000 | Apr 13 09:45 PM | | Cooke Shane | Director | Apr 11 | Sale | 35.08 | 5,000 | 175,382 | 0 | Apr 13 09:45 PM | | COLLIER RICHARD T | Director | Apr 05 | Option Exercise | 6.41 | 5,000 | 32,050 | 6,219 | Apr 07 09:47 PM | | COLLIER RICHARD T | Director | Apr 05 | Sale | 39.41 | 5,000 | 197,027 | 1,219 | Apr 07 09:47 PM | | EcoR1 Capital, LLC | 10% Owner | Jan 12 | Buy | 37.50 | 300,000 | 11,250,300 | 11,584,280 | Jan 12 06:12 PM | | Selkoe Dennis J. | Director | Jan 03 | Option Exercise | 9.23 | 5,000 | 46,150 | 7,845 | Jan 05 09:02 PM | | Selkoe Dennis J. | Director | Jan 03 | Sale | 47.45 | 5,000 | 237,233 | 2,845 | Jan 05 09:02 PM | | Walker Karin L | Chief Accounting Officer | Nov 23 | Option Exercise | 15.04 | 4,519 | 67,966 | 4,519 | Nov 26 09:19 PM | | Walker Karin L | Chief Accounting Officer | Nov 23 | Sale | 57.88 | 4,519 | 261,573 | 0 | Nov 26 09:19 PM | | Malecek Michael J | See Remarks | Nov 19 | Option Exercise | 10.27 | 10,000 | 102,700 | 10,000 | Nov 19 09:32 PM | | Malecek Michael J | See Remarks | Nov 19 | Sale | 55.00 | 10,000 | 550,000 | 0 | Nov 19 09:32 PM | | Karp Carol D. | Chief Regulatory Officer | Nov 01 | Option Exercise | 15.04 | 10,000 | 150,400 | 10,000 | Nov 03 09:17 PM | | Karp Carol D. | Chief Regulatory Officer | Nov 01 | Sale | 57.18 | 10,000 | 571,818 | 0 | Nov 03 09:17 PM | | Malecek Michael J | See Remarks | Oct 27 | Option Exercise | 10.27 | 10,000 | 102,700 | 10,000 | Oct 29 05:00 PM | | Malecek Michael J | See Remarks | Oct 27 | Sale | 58.52 | 10,000 | 585,250 | 0 | Oct 29 05:00 PM | | Walker Karin L | Chief Accounting Officer | Oct 20 | Option Exercise | 16.97 | 23,000 | 390,230 | 23,000 | Oct 22 05:53 PM | | Walker Karin L | Chief Accounting Officer | Oct 20 | Sale | 60.25 | 23,000 | 1,385,823 | 0 | Oct 22 05:53 PM | | Karp Carol D. | Chief Regulatory Officer | Oct 01 | Option Exercise | 15.04 | 10,000 | 150,400 | 10,000 | Oct 01 08:46 PM | | Selkoe Dennis J. | Director | Oct 01 | Option Exercise | 9.23 | 5,000 | 46,150 | 7,845 | Oct 01 09:18 PM | | Karp Carol D. | Chief Regulatory Officer | Oct 01 | Sale | 68.23 | 10,000 | 682,336 | 0 | Oct 01 08:46 PM | | Selkoe Dennis J. | Director | Oct 01 | Sale | 67.84 | 5,000 | 339,176 | 2,845 | Oct 01 09:18 PM | | Karp Carol D. | Chief Regulatory Officer | Sep 09 | Option Exercise | 15.04 | 10,000 | 150,400 | 10,000 | Sep 10 05:06 PM | | Karp Carol D. | Chief Regulatory Officer | Sep 09 | Sale | 71.98 | 10,000 | 719,847 | 0 | Sep 10 05:06 PM | | Selkoe Dennis J. | Director | Jul 30 | Option Exercise | 14.26 | 5,000 | 71,315 | 7,845 | Jul 30 08:04 PM | | Selkoe Dennis J. | Director | Jul 30 | Sale | 49.47 | 5,000 | 247,374 | 2,845 | Jul 30 08:04 PM | | HENNEY CHRISTOPHER S | Director | Jul 14 | Option Exercise | 11.33 | 11,108 | 125,854 | 11,108 | Jul 16 04:02 PM | | HENNEY CHRISTOPHER S | Director | Jul 14 | Sale | 55.46 | 11,108 | 616,020 | 0 | Jul 16 04:02 PM | | HENNEY CHRISTOPHER S | Director | Jul 12 | Option Exercise | 9.79 | 23,892 | 233,946 | 17,500 | Jul 12 09:37 PM | | HENNEY CHRISTOPHER S | Director | Jul 12 | Sale | 55.51 | 23,892 | 1,326,128 | 0 | Jul 12 09:37 PM |
|
